Pfizer Inc. (NYSE:PFE) will hold an investor call on Tuesday to provide information on the full year 2025. financial guidance.
Ahead of the call, Goldman Sachs outlined its expectations for guidance and commentary over the coming year.
The analyst anticipates that Pfizer’s management will lead to EPS in the mid-to-high $2 range, with core business growth offset by $0.30 in favorable but non-recurring items during 2024.
Pfizer highlighted several factors affecting its 2024 EPS that will not carry over to 2025.
2024 EPS includes one-time increases: $1.2 billion profit from Paxlovid storage and a U.S. government adjustment and capital income for its participation in Haleon Plc (NYSE:HLN). However, Haleon’s revenue will not appear in 2025, as Pfizer’s ownership in Haleon is falling below 20%.
Goldman forecast 2025 revenue of $64.9 billion and earnings per share of $3.13, which compares to consensus estimates of $63.2 billion and $2.89, respectively.
Goldman Sachs notes that the impact of the Part D IRA redesign will likely be addressed in the company’s forecasts for 2025. However, the analyst does not expect the details to be broken down by individual products, but rather based on the portfolio general commercial.
The analyst expects Paxlovid sales of $4.3 billion versus the consensus of $3.7 billion, although a little more conservative on Vyndaqel sales of $5.9 billion versus the consensus of $6.2 billion.
So far this year, Eliquis has performed well, showing 12% growth thanks to market expansion and increased market share. This growth has been supported by Pfizer’s commercial team and driven by Part D catastrophic coverage in 2024.
Looking ahead to 2025, Pfizer expects continued growth opportunities driven by market expansion and the potential for further share gains.
“We highlight dynamics on key themes and frame potential talking points with possible extrapolations beyond Pfizer specifically, noting that it is the only large-cap pharma company in our coverage that we expect to weigh in on in 2025 heading into the new year,” Goldman. writes the analyst.
Price action: PFE shares were down 0.39% at $25.48 at last check on Monday.
Read next:
Photo via Shutterstock.
|
Date |
Firm |
Action |
Of |
TO |
|---|---|---|---|---|
|
February 2022 |
Morgan Stanley |
Maintains |
equal weight |
|
|
January 2022 |
Wells Fargo |
Maintains |
Overweight |
|
|
January 2022 |
Values B of A |
Updates |
Neutral |
Buy |
See more analyst ratings for PFE
See the latest analyst ratings
Up next: Transform your trading with Benzinga Edge’s one-of-a-kind market trading ideas and tools. Click now to access unique information that can position you ahead in today’s competitive market.
